###begin article-title 0
###xml 16 25 16 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Neuroblastoma is a solid tumour of childhood often with an unfavourable outcome. One common genetic feature in aggressive tumours is 1p-deletion.
###end p 3
###begin p 4
###xml 19 23 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 167 172 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 187 192 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 230 236 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc </italic>
###xml 257 262 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
The alpha-enolase (ENO1) gene is located in chromosome region 1p36.2, within the common region of deletion in neuroblastoma. One alternative translated product of the ENO1 gene, known as MBP-1, acts as a negative regulator of the c-myc oncogene, making the ENO1 gene a candidate as a tumour suppressor gene.
###end p 4
###begin title 5
Methods
###end title 5
###begin p 6
###xml 64 73 64 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Methods used in this study are transfection of cDNA-vectors and in vitro transcribed mRNA, cell growth assay, TUNEL-assay, real-time RT-PCR (TaqMan) for expression studies, genomic sequencing and DHPLC for mutation detection.
###end p 6
###begin title 7
Results
###end title 7
###begin p 8
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 318 327 318 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 460 465 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
Here we demonstrate that transfection of ENO1 cDNA into 1p-deleted neuroblastoma cell lines causes' reduced number of viable cells over time compared to a negative control and that it induces apoptosis. Interestingly, a similar but much stronger dose-dependent reduction of cell growth was observed by transfection of in vitro transcribed ENO1 mRNA into neuroblastoma cells. These effects could also be shown in non-neuroblastoma cells (293-cells), indicating ENO1 to have general tumour suppressor activity.
###end p 8
###begin p 9
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 310 314 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
Expression of ENO1 is detectable in primary neuroblastomas of all different stages and no difference in the level of expression can be detected between 1p-deleted and 1p-intact tumour samples. Although small numbers (11 primary neuroblastomas), there is some evidence that Stage 4 tumours has a lower level of ENO1-mRNA than Stage 2 tumours (p = 0.01). However, mutation screening of 44 primary neuroblastomas of all different stages, failed to detect any mutations.
###end p 9
###begin title 10
Conclusion
###end title 10
###begin p 11
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
Our studies indicate that ENO1 has tumour suppressor activity and that high level of ENO1 expression has growth inhibitory effects.
###end p 11
###begin title 12
Background
###end title 12
###begin p 13
###xml 207 211 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 523 524 523 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 410 417 <span type="species:ncbi:9606">patient</span>
Neuroblastoma is the most common solid tumour of childhood. It is a tumour of the postganglionic sympathetic nervous system. The most common genetic features of this tumour are amplification of the oncogene MYCN, deletions of part of chromosome arm 1p, gain of parts of 17q and triploidy. MYCN amplification, 1p-loss and 17q gain are strongly associated with aggressive tumour and unfavourable outcome for the patient, whereas triploidy is associated with low stage neuroblastomas and a favourable outcome. For review see [1].
###end p 13
###begin p 14
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 668 672 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 675 676 675 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 679 684 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CORT </italic>
###xml 685 686 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 689 694 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DFFA </italic>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 697 698 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBE4B </italic>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 713 720 713 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APITD1 </italic>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 726 737 726 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIF1B-beta </italic>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 743 755 743 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIF1B-alpha </italic>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 761 766 761 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SDHB </italic>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 772 779 772 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDC2L1 </italic>
###xml 780 782 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 788 793 788 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HKR3 </italic>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 799 803 799 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAN </italic>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 809 813 809 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ID3 </italic>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 819 825 819 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR2 </italic>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
A smallest region of overlap of deletion has earlier been determined in primary neuroblastomas by our group to an approximately 2 Mbp region between polymorphic markers D1S214 and D1S244 [2,3]. Although other research groups have defined regions telomeric to marker D1S214 [4], still the major part of all 1p-deleted neuroblastoma tumours does include this region. We hypothesise that this region harbours one or more tumour suppressor genes, which plays an important role in neuroblastoma tumourigenesis. In previous studies a number of different candidate genes from the critical region have been screened for mutations and expression differences. Some examples are TP73[5,6], CORT [7], DFFA [8,9], UBE4B [10], APITD1 [11], KIF1B-beta [12], KIF1B-alpha [13], SDHB [14], CDC2L1 [15,16], HKR3 [17], DAN [18], ID3 [19], TNFR2 [20]. However, there is still no conclusive evidence that anyone of these candidate genes could function as a neuroblastoma tumour suppressor gene.
###end p 14
###begin p 15
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
Functional evidence for a neuroblastoma tumour suppressor gene on chromosome 1 was obtained in cell-hybrid studies [21]. The addition of an entire chromosome 1 to a 1p-deleted cell line was shown to induce cell death and/or differentiation indicating that it should be possible to functionally identify the neuroblastoma tumour suppressor gene by introducing candidate genes into 1p-deleted neuroblastoma cells, and then monitoring the cells for reduced cell growth, apoptosis and differentiation.
###end p 15
###begin p 16
###xml 278 280 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 344 349 340 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 352 354 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 490 492 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 528 533 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 583 585 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 588 594 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 659 661 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 796 798 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 894 898 886 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 1021 1026 1013 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1063 1069 1055 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 1094 1098 1086 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 1186 1197 1178 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1/MBP-1 </italic>
###xml 1200 1204 1192 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 1247 1251 1239 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
Non-neural enolase or alpha-enolase (ENO1) is an enzyme in the glycolytic pathway catalysing the formation of phosphoenolpyruvate from 2-phosphoglycerate. This gene also encodes an alternatively translated product, by initiating the translation at the Met-97 residue in exon 5 [22]. This product was earlier known as the Myc-binding protein-1 (MBP-1) [23]. The long 48 kDa form of alpha-enolase has enzymatic activity and, depending on cell type, a cytoplasmic and/or nuclear localization [24], whereas the shorter 37 kDa form (MBP-1) is preferentially localized in the cell nuclei [25]. MBP-1 appears to function as a negative regulator of c-myc expression [26]. The c-myc protooncogene is a DNA-binding phosphoprotein that plays an important role in cell growth regulation and differentiation [27]. A major genetic feature of aggressive neuroblastoma tumours is amplification of the oncogene MYCN, and this is often associated with loss of chromosome region 1p. Even though there are similarities between the c-myc and MYCN oncogenes, there is no evidence that MBP-1 is able to interact with MYCN. Still it would be of interest to investigate this further by comparing the actions of ENO1/MBP-1 in MYCN-amplified cells relative to cells with no MYCN-amplification.
###end p 16
###begin p 17
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 455 457 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 532 537 524 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 750 754 742 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 907 911 899 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 991 996 983 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 138 147 <span type="species:ncbi:10090">nude mice</span>
###xml 258 267 <span type="species:ncbi:10090">nude mice</span>
Enforced overexpression of MBP-1 by transfection of MBP-1 cDNA into human breast carcinoma cells was shown to inhibit tumour formation in nude mice [28], and the carboxyl-terminal repressor domain of MBP-1 has been shown to regress prostate tumour growth in nude mice [29]. Another study has shown that alpha-enolase is frequently down-regulated in non-small cell lung cancer and that low levels of alpha-enolase predicts aggressive biological behaviour [30]. Our first hypothesis in designing this study was that the shorter form (MBP-1) would play an important role in cell growth regulation in neuroblastoma, considering its localization to the nucleus and its known function as a negative regulator of c-myc expression, and that the longer form (ENO1) would not be directly involved in altered cell growth. This hypothesis was proven to be false, since we in this study could show that the longer form (ENO1) alone has equal or stronger effect on the cell viability and apoptosis, as do MBP-1.
###end p 17
###begin p 18
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CORT</italic>
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DFFA</italic>
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ICAT</italic>
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEX14 </italic>
###xml 122 125 122 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGD</italic>
###xml 206 210 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 251 256 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 350 359 350 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 406 411 406 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 531 536 531 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 594 599 594 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 603 609 603 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 617 621 617 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 664 668 664 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
In this paper we have functionally screened six candidate genes from the 1p36.2 region (CORT, DFFA, ENO1, ICAT, PEX14 and PGD) in neuroblastoma cells. We have furthermore performed a more detailed study of ENO1, including its shorter translation form MBP-1, and a mutated form of ENO1 that eliminates the possibility of production of MBP-1, by using in vitro transcribed mRNA. Our studies demonstrate that ENO1 overexpression in both neuroblastoma and 293 cells significantly reduces cell growth and induces apoptosis, implicating ENO1 in tumourigenesis. Similar effects could be seen for both ENO1 and MBP-1 in both MYCN-amplified cells (IMR32) and cells with no MYCN-amplification (SK-N-AS).
###end p 18
###begin title 19
Methods
###end title 19
###begin title 20
cDNA-constructs
###end title 20
###begin p 21
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DFFA </italic>
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ICAT </italic>
###xml 94 100 94 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEX14 </italic>
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGD </italic>
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CORT </italic>
###xml 396 400 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DFFA</italic>
###xml 402 406 402 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 408 413 408 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ICAT </italic>
###xml 417 422 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CORT </italic>
###xml 424 429 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NotI </italic>
###xml 470 473 470 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 507 511 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGD </italic>
###xml 515 526 515 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEX14 NotI </italic>
###xml 712 717 712 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP </italic>
###xml 801 805 801 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DFFA</italic>
###xml 807 813 807 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEX14 </italic>
###xml 817 821 817 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGD </italic>
###xml 665 668 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Full length IMAGE cDNA clones of the genes DFFA [GenBank:], ENO1 [GenBank:], ICAT [GenBank:], PEX14 [GenBank:], PGD [GenBank:] (HGMP Resource Centre, UK) and a clone for CORT [Genbank:] (Incyte Genomics, Palo Alto, CA) were used as templates to make a full length PCR product not including the polyA signal and introducing cloning sites in the ends (primer sequences available upon request). For DFFA, ENO1, ICAT and CORT a NotI site was introduced at the 3' end and an EcoRI site at the 5' end. For clones PGD and PEX14 NotI was used at both ends. The PCR products were digested and ligated into the vector pIRES-EGFP (Clontech, Palo Alto, CA), which includes the CMV promoter for eukaryotic expression and the EGFP gene for fluorescence detection, using standard procedures. The resulting clones of DFFA, PEX14 and PGD were also confirmed by restriction digestion (data not shown). Large-scale plasmid DNA preparations were performed using the Qiagen Plasmid Maxi protocol (Qiagen, Hilden, Germany). All constructs were finally sequence confirmed by BigDyeTerminator sequencing, performed on ABI 3700 (Applied Biosystems).
###end p 21
###begin p 22
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 87 92 87 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 158 164 158 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 288 289 288 289 <underline xmlns:xlink="http://www.w3.org/1999/xlink">C</underline>
###xml 297 298 297 298 <underline xmlns:xlink="http://www.w3.org/1999/xlink">C</underline>
###xml 419 423 419 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 735 740 734 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 797 800 796 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 803 806 802 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Not</italic>
###xml 839 841 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 915 920 914 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 924 929 923 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ClaI </italic>
###xml 973 975 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
A mutated variant of the ENO1 cDNA was constructed by introducing two mutations in the ENO1 sequence, eliminating the alternative translation start codons of MBP-1 (Fig. 1A). The mutations were introduced into the ENO1 sequence by PCR using the double-mutated forward primer fp1: 5'-CTGATCATCGAGATCGA TGGAAC-3', in combination with the reverse primer rp2: 5'-ACAAAGAATTCCGG GGATCTAGCCT GTGG-3' for 30 cycles, using the ENO1-pIRES-EGFP construct as a template. 0.1 mul of the PCR-product was then used as template in an additional PCR reaction using the primers fp3: 5'-CAGCAGCGGCCGCTTCCTCTC CTAGGCG-3' and rp2: 5'-ACAAAGAATTCCGGGGATCTAGCCTGTGG-3' for 30 cycles of PCR, to incorporate the mutations in the full-length gene product. The ENO1 mutant fragment was cloned into the pIRES-EGFP vector by EcoRI/NotI digestion and religation (Fig. 1B). The mutations were also confirmed by digestion of the PCR product with BclI and ClaI that only digest the mutated sequence (Fig. 1C).
###end p 22
###begin title 23
###xml 14 23 14 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Production of in vitro transcribed mRNA
###end title 23
###begin p 24
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 190 195 190 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 199 203 199 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 293 295 293 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink">30</sub>
###xml 346 352 346 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 438 440 438 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">30</sub>
###xml 469 473 469 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
A DNA fragment containing the coding region of the ENO1 gene linked to the Sp6 promoter sequence and a polyA tail at the end of the fragment was constructed by PCR. The primers used for the ENO1 and ENO1mut mRNAs were fp: 5'-ATTTAGGTGACACTATAGAAGAGACCCAGTGGCTAGAAGTTCACCATG-3' and rp: 5'-GG(T)30CCGGGGATCTAGCCTGTGG-3'. Similarly, the primers for MBP-1 mRNA were fp: 5'-ATTTAGGTGACACTATAGAAGAGAACAAGAGAAGATTGACAAACTGATG-3' and rp: 5'-GG(T)30CCGGGGATCTAGCCTGTGG-3' using ENO1-mut-pIRES-EGFP-vector as a template. The PCR was performed using High Fidelity Taq Polymerase (Roche, Mannheim, Germany) according to supplier's protocol with an annealing temperature of 58degreesC and 25 cycles of PCR.
###end p 24
###begin p 25
###xml 62 71 62 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 373 378 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP </italic>
###xml 455 464 443 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
500 ng of the PCR-product (663 bp) was used as a template for in vitro mRNA using mMESSAGE mMachine (Ambion, Austin, TX). The procedure was according to supplier's protocol using 4 hours incubation at 37degreesC. The mRNA was DNaseI treated for 15 min at 37degreesC and LiCl-precipitated before size and concentration evaluation by agarose gel electrophoresis. The control EGFP mRNA was produced using an EcoRI-digested Sp6-EGFP vector as template in the in vitro mRNA reaction.
###end p 25
###begin p 26
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP </italic>
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
The concentrations of EGFP and ENO1 mRNA preparations were evaluated on agarose and adjusted to be equal for transfection studies.
###end p 26
###begin title 27
Tissue culture
###end title 27
###begin p 28
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 101 106 <span type="species:ncbi:9606">human</span>
###xml 144 149 <span type="species:ncbi:9606">human</span>
###xml 254 258 <span type="species:ncbi:9913">Calf</span>
The 1p-deleted neuroblastoma cell lines SK-N-AS and IMR32 (MYCN-amplified) (ATCC, Manassas, VA), the human kidney derived cell line 293 and the human erythroleukaemic cell line K562 were cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% Fetal Calf Serum (FCS) at 37degreesC using standard procedures. On the day before transfection the cell lines were split into new culture flasks and their viability tested by Trypan Blue staining. Flasks with 60-80% cell confluence were used in transfection experiments. Immediately before the transfection procedure the SK-N-AS cells, the IMR32 cells and the 293 cells were trypsinized and washed twice with PBS and the cell numbers were calculated using Trypan Blue staining. The suspension cells K562 were used only if the viability was 90% or more on the day of transfection.
###end p 28
###begin title 29
Transfection of cDNA vectors
###end title 29
###begin p 30
###xml 134 136 133 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
Transfection of the cell lines SK-N-AS and 293 with the cDNA constructs was performed by electroporation using 10 mug of DNA in 4 x 106 cells in a 0.4 cm cuvette in 500 mul Opti-MEM I (Invitrogen, Carlsbad, CA) at 300 V, 950 muF, infinity Omega, using a Bio-Rad Gene Pulser II (Bio-Rad, Hercules, CA). The transfection efficiency of SK-N-AS and 293 was tested by transfection of the plasmid pEGFP-N22, followed by estimation of the number of green cells detected by FACS analysis after two days of growth in DMEM 10 % FCS. The transfection efficiency for the SK-N-AS and 293 cells was approximately 90% under these conditions.
###end p 30
###begin p 31
###xml 204 206 183 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
For IMR32 cells, transfections were performed using Lipofectaminetrade mark 2000 (Invitrogen). 12 mug of DNA and 25 mul of Lipofectaminetrade mark 2000 in 1200 mul Opti-MEM I were used for transfecting 106 cells in 5 ml of DMEM, 10% FCS. Transfection efficiency was estimated to be 60 % by fluorescence microscopy of pEGFP-N22 transfected cells, two days after transfection.
###end p 31
###begin p 32
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
Transfection with all plasmid constructs was performed twice using SK-N-AS cells. The ENO1 construct and empty vector control were also transfected in four different experiments into SK-N-AS cells and twice into IMR32 and 293 cells.
###end p 32
###begin title 33
Transfection of mRNA
###end title 33
###begin p 34
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 113 115 113 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 242 247 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP </italic>
###xml 264 269 261 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 284 289 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP </italic>
###xml 306 311 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 570 572 545 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 610 612 585 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
The transfections were performed in a 12-well plate using 4 x 105cells/well for SK-N-AS and K562 cells and 7 x 105 cells/well for 293 cells, all in 2 ml DMEM with 10% FCS per well. For each transfection a total of 1.5 mug of mRNA (A: 1.5 mug EGFP mRNA; B: 0.3 mug ENO1 mRNA + 1.2 mug EGFP mRNA; C: 1.5 mug ENO1 mRNA) and 5 mul Lipofectaminetrade mark 2000 were used. The mRNA and the Lipofectaminetrade mark 2000 were incubated together for 30 min in 200 mul Opti-MEM I and then added to the cell suspensions. The cells were immediately divided into 96-well plates at 104 cells/well (SK-N-AS, K562) or 1.7 x 104 cells/well (293) (50 mul/well), and incubated at 37degreesC for 5 hours before an extra 50 mul DMEM with 10% FCS was added. The cells were incubated for 1-4 days in 37degreesC for cell growth studies.
###end p 34
###begin title 35
Apoptosis assay
###end title 35
###begin p 36
After transfection, the cells were allowed to attach for two hours in a tissue culture plate (6 well) before the medium was replaced by fresh DMEM 10% FCS. Then the cells were grown for two days before all cells, both in medium and attached cells (trypsinized) were washed with PBS and fixed in a final concentration of 2% paraformaldehyde.
###end p 36
###begin p 37
The fixed cells were TUNEL stained using the In Situ Cell Death Detection Kit TMR-red kit (Roche, Mannheim, Germany) according to supplier's protocol. This stains all apoptotic cells red. The cells were then analysed by FACS analysis.
###end p 37
###begin title 38
Cell growth assay
###end title 38
###begin p 39
###xml 165 167 165 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
After transfection, the cells were divided into 96-well plates. Cells with each different construct were divided into 8 wells/plate, in four different plates with 104 cells in 100 mul DMEM 10 % FCS per well. One plate was used every day for four days after transfection to monitor cell growth. 20 mul of CellTiter96 Aqueous One Solution (Cell Proliferation Assay, Promega, Madison, WI) was added to each well and incubated in a humid dark chamber at 37degreesC for four hours. The absorbance was detected at 490 nm by an ELISA-reader (Labsystems Multiscan RC, Helsinki, Finland). The results were compared to a standard curve to calculate the number of viable cells per well each day. The mean number of cells in the 8 wells evaluated per day per construct was used in evaluating the results.
###end p 39
###begin p 40
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP </italic>
The transfection efficiency was evaluated one day after transfection using fluorescence microscopy, by counting the number of green cells in the pEGFP-N22 or EGFP mRNA experiments.
###end p 40
###begin title 41
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient material
###end title 41
###begin p 42
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Frozen (-70degreesC) tumour samples from 44 neuroblastoma patients; 4 Stage 1 (1 1p-deleted), 4 Stage 2, 14 Stage 3 (7 1p-deleted), 20 Stage 4 (14 1p-deleted), 2 Stage 4S; 2 ganglioneuromas and 2 teratomas (1 1p-deleted) were used in the study.
###end p 42
###begin p 43
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 186 193 <span type="species:ncbi:9606">patient</span>
The tumours were staged according to the International Neuroblastoma Staging System criteria [31,32]. The 1p-deletion status has been previously evaluated [2,16]. DNA was extracted from patient samples using standard procedures.
###end p 43
###begin title 44
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
Expression studies of ENO1
###end title 44
###begin title 45
cDNA preparation
###end title 45
###begin p 46
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
Total RNA was extracted from frozen neuroblastoma tumour tissue from 11 primary neuroblastomas; 4 Stage 2 tumours from patients with no evidence of disease after treatment; 7 Stage 4 tumours (4 1p-deleted), all from patients dead of disease and 7 neuroblastoma cell lines (4 1p-deleted) using RNeasy RNA extraction kit (Qiagen). 2.4 mug total-RNA of each sample was reversed transcribed to cDNA using Superscript II (Amersham, Buckinghamshire, UK) and random hexamer primers, all according to supplier's protocol.
###end p 46
###begin title 47
Real time RT-PCR
###end title 47
###begin p 48
###xml 77 81 77 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 272 277 <span type="species:ncbi:9606">Human</span>
TaqMan primers and probes were derived from the commercially available TaqMan(R) Assays-on-Demand Gene Expression Products. To select the most appropriate endogenous control for the real-time RT-PCR quantification analysis of neuroblastoma primary tumours, we used TaqMan Human Endogenous Control Plate (catalog number: 4309921, Applied Biosystems, Foster City, CA). Analysis was performed according to supplier's protocol.
###end p 48
###begin p 49
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB </italic>
###xml 261 265 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 270 271 264 265 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 320 322 310 312 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 407 412 397 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB </italic>
###xml 532 533 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
To select the most appropriate endogenous control for the real-time PCR quantification analysis, we tested eight different primary NB samples of different stages for their expression levels of ten commonly used housekeeping genes. GUSB (beta-glucuronidase) and B2M (beta2-microglobulin) showed least variations in DeltaCT levels, and were expressed at constant levels in all samples regardless of NB-stage. GUSB was selected, and further used as an internal reference for normalization in the real-time PCR quantification analysis [9].
###end p 49
###begin p 50
###xml 65 69 65 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Real-time RT-PCR was performed in 384-well plates using ABI PRISM(R) 7900HT Sequence Detection System (Applied Biosystems). Amplification reactions (10 mul) were carried out in duplicate with 1 mul of 1:10 diluted template cDNA according to manufacturer's protocol (Applied Biosystems). In each assay, a standard curve with six cDNA dilutions was recorded and two non-template controls were included.
###end p 50
###begin p 51
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
###xml 359 363 356 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB</italic>
Quantification was performed by the standard-curve method. The mean CT-value for duplicates was calculated, and the gene concentration (or gene copy number) of test samples was interpolated based on standard curves. All samples were normalized by dividing the concentration of the test gene with the concentration of the housekeeping gene beta-glucuronidase (GUSB) in the same cDNA sample.
###end p 51
###begin title 52
Statistical analysis
###end title 52
###begin p 53
Statistical analysis was done with Student's two-sided t-test on each group of tumors; low-stage and high stage tumors; and for 1p-deleted and not 1p-deleted tumors for the expression study.
###end p 53
###begin p 54
In the transfection study, Student's two-sided t-test was used to compare cell numbers in each experiment at 1, 2, 3 and 4 days after transfection.
###end p 54
###begin title 55
Mutation screening
###end title 55
###begin p 56
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
Mutation screening of all exonic sequences, selected intronic sequences and the promoter region of ENO1 was performed on genomic DNA from 48 primary neuroblastoma tumours of all different stages. The different regions were amplified by PCR and the PCR products were screened for mutations using either BigDyeTerminator sequencing, performed on ABI 3700 (Applied Biosystems) and/or DHPLC (WAVE) (Becton, Dickinson and Company) all according to general protocols of the suppliers. PCR-primers were designed to include the entire exon plus exon-intron boundaries. PCR primers and amplification data are available on request.
###end p 56
###begin title 57
Results
###end title 57
###begin title 58
Functional studies
###end title 58
###begin p 59
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
TUNEL staining, followed by FACS-analysis, of ENO1-transfected SK-N-AS neuroblastoma cells two days after transfection showed a higher degree of apoptotic cells (59%) than with the empty vector control (9%) or any of the other constructs tested (8-26% apoptotic cells), (Table 1, Fig. 2).
###end p 59
###begin p 60
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DFFA</italic>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGD </italic>
###xml 301 307 301 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEX14 </italic>
###xml 371 376 371 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ICAT </italic>
###xml 407 412 407 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CORT </italic>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 485 486 485 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 524 528 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 609 613 609 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 725 730 725 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 792 793 792 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
The DNA transfection studies also showed that the ENO1 gene did have the strongest and most consistent effect (approximately 20% reduction) on the growth rate of 1p-deleted neuroblastoma cells (SK-N-AS and IMR32) compared to an empty vector control (Table 2, Fig. 3). In the same assay, DFFA, PGD and PEX14 showed an approximately 10% reduction in cell growth (SK-N-AS), ICAT did not show any reduction and CORT showed very variable effects (from -10% to 18% reduction) (Table 2, Fig. 3). Transfection experiments using the ENO1-gene compared to empty vector control were also performed in the 1p-deleted and MYCN-amplified neuroblastoma cell line IMR32 and the non-neuroblastoma cell line 293. These experiments showed that ENO1 reduced cell growth by 20-30 % in all three cell lines (Table 2).
###end p 60
###begin p 61
###xml 399 408 399 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 451 455 451 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
Interpretation of cell growth studies after transfection of plasmids carrying various genes may be complicated by the fact that only a fraction of cells express the relevant gene, whereas the growth of the remaining cells may continue unaffected. In an effort to ensure that most cells express the relevant gene after transfection, we have also investigated transfection of each one of the genes as in vitro transcribed mRNA. Preliminary studies with EGFP-mRNA showed that the transfection efficiency, as determined by fluorescence microscopy 24 hours after transfection, was 90% for SK-N-AS cells, 60% for K562 cells and 90% for 293 cells.
###end p 61
###begin p 62
###xml 67 71 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 76 80 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 236 240 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 271 272 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 279 281 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 283 285 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 315 320 313 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 420 421 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 428 430 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 449 454 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
Our mRNA-transfection experiments showed that by adding 1.5 mug of ENO1- or ENO1-mut-mRNA to the neuroblastoma cell line SK-N-AS, the cell numbers were reduced by 60% after 24 hours, and by 80% after 2-4 days of incubation, compared to EGFP-mRNA transfected cells (Table 3, Fig. 4A &4B). On the other hand, 1.5 mug MBP-1-mRNA reduced the cell growth rate by 50% after 24 hours and 70% 2-4 days after transfection (Table 3, Fig. 4B), indicating that MBP-1-mRNA is less effective than the full length transcripts.
###end p 62
###begin p 63
###xml 13 17 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 26 30 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 62 66 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 214 219 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 247 251 242 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 346 347 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 354 356 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
When 0.3 mug ENO1-mRNA or ENO1-mut-mRNA mixed with 1.2 mug of EGFP-mRNA were used, the reduction in cell numbers after 24 hours was 40%, and 60% respectively after 2-4 days. As with the 1.5 mug experiment, 0.3 mug MBP-1-mRNA mixed with 1.2 mug of EGFP-mRNA gave a lower reduction of 30% after 24 hours, and 40% 2-4 days after transfection (Table 3, Fig. 4C).
###end p 63
###begin p 64
###xml 62 66 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 157 162 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP </italic>
###xml 195 196 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 203 205 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 220 224 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP1</italic>
###xml 229 233 227 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 369 373 366 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 490 494 487 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 503 509 500 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 568 569 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
In 293 cells a large reduction in cell numbers in the 1.5 mug ENO1-mRNA experiments could be seen after 24 hours (50%), and after 2-4 days (90%) compared to EGFP transfected control cells (Table 3, Fig. 4A). For 1.5 mug MBP1- or ENO1-mut-mRNA the reduction in 293 cells was 40% after 24 hours, and 70-80% 2-4 days after transfection. A parallel experiment with 0.3 mug ENO1-mRNA showed about 60% reduction 2-4 days after transfection compared to control cells, while in the same experiment ENO1-mut and MBP-1 mRNAs showed a 30% and a 50% reduction respectively (Table 3).
###end p 64
###begin p 65
###xml 120 121 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
In K562 cells, the cell numbers 24 hours after transfection were not significantly different between experiments (Table 3).
###end p 65
###begin title 66
Expression studies
###end title 66
###begin p 67
###xml 255 259 255 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
No difference in expression levels could be detected between 1p-deleted cell lines (average relative concentration of 1.07) and 1p-intact cell lines (average relative concentration of 1.08). Also in Stage 4 neuroblastoma primary tumours, no difference in ENO1-expression could be detected between 1p-deleted (average relative concentration 0.25) and 1p-intact samples (average relative concentration of 0.19) (Fig. 5).
###end p 67
###begin p 68
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
Real time-PCR studies of the ENO1 gene on cDNA-samples showed a 55% reduction (p = 0.01) of ENO1-mRNA levels in stage 4 neuroblastoma tumours compared to stage 2 tumour levels (average relative concentration of 0.5 in stage 2 tumours compared to 0.23 in stage 4 tumours). This reduction was independent on the 1p-deletion status of the tumour sample (Fig. 5).
###end p 68
###begin title 69
Mutation screening
###end title 69
###begin p 70
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
The mutation screening of the promoter region and of all exonic sequences of ENO1, including exon/intron boundaries, and of introns 5-7 in 48 primary neuroblastoma samples of different stages did not reveal any mutations (data not shown).
###end p 70
###begin title 71
Discussion
###end title 71
###begin p 72
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 698 703 698 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 1212 1217 1212 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 1486 1491 1486 1491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 1738 1744 1738 1744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 1859 1861 1859 1861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1864 1870 1864 1870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 1938 1943 1938 1943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 1949 1951 1949 1951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1952 1954 1952 1954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 2132 2137 2132 2137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 2273 2277 2269 2273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 2572 2576 2568 2572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 2653 2657 2649 2653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 2747 2752 2743 2748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 2855 2860 2851 2856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 2863 2867 2859 2863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 2914 2919 2910 2915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 2956 2961 2952 2957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 2962 2967 2958 2963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 3034 3036 3030 3032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 3132 3137 3128 3133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 3196 3201 3192 3197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 823 828 <span type="species:ncbi:9606">human</span>
###xml 1749 1754 <span type="species:ncbi:9606">human</span>
###xml 1848 1857 <span type="species:ncbi:10090">nude mice</span>
The aim of this study was to functionally identify a tumour suppressor gene in the commonly deleted region 1p36 in advanced stage neuroblastoma tumours. We were in fact able to identify one gene, ENO1, located in the smallest region of overlap of deletion in neuroblastoma, which did seem to have tumour suppressor activity. That is, by introducing this gene as a cDNA construct into neuroblastoma cells, the number of viable cells over time was reduced, and the number of apoptotic cells was increased. These two results are probably just two ways of monitoring the same thing. A higher degree of cell death will obviously slow down number of viable cells over time. We also tested the ability of ENO1 cDNA to slow down cell growth in other cell types that did not have a deletion of 1p. Here we choose the 293 cell line (human transformed kidney cells). Other cells that could add valuable information would be a neuroblastoma cell line with intact 1p (such as SK-N-SH or SK-N-F1), we were though unable to get a satisfactory transfection efficiency in these cell lines for this study, and thus choose to use the 293 cells that worked very well, that also adds valuable information about the general effect of ENO1 on cells with intact 1p. In this study we monitor viable cells over time after transfection, thus it is crucial to have high percentage of transfected cells otherwise your experiment would easily be overgrown by the untransfected cell population. After transfection of ENO1 into the 293 cells the same results were obtained as with the neuroblastoma cell lines, that is, the number of viable cells over time was reduced by 20-40 %. These results are concordant with the results of Ray and co-workers that transfection of MBP-1 into human breast carcinoma cells showed reduction of cell growth and inhibition of tumour formation in nude mice [28]. MBP-1 was later demonstrated to be a shorter translational variant of the ENO1 gene [22,25]. The localization of the gene in the 1p36.2 chromosomal region makes it a very interesting gene for neuroblastoma tumourigenesis and one hypothesis is that one deleted copy of ENO1 in the neuroblastoma cells would result in lower levels of alpha-enolase, and thus these cells would have a stronger response when more ENO1-mRNA is added. However, in this study we did see an equally strong effect in the chromosome 1 intact cells 293. Maybe the level of ENO1 is crucial in the cells, and by adding too much of this gene product shifts the balance easily and makes the cell go into apoptosis. Also we could see in the ENO1-expession study that the 1p-deleted cell lines did not have lower levels of ENO1-mRNA compared to the 1p-intact cell lines. This adds to the hypothesis that the level of ENO1 expression might be crucial. One hypothesis was that it might be a difference in the response to added ENO1 in MYCN-amplified cells (IMR32) and cells with normal MYCN (SK-N-AS), since the shorter form of ENO1 (MBP-1) appears to function as a negative regulator of c-myc expression [26]. No difference could however be seen in the response in these two cell lines, indicating that ENO1 has growth inhibitory properties independent of effects on MYCN regulation.
###end p 72
###begin p 73
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 366 372 366 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APITD1</italic>
###xml 421 428 421 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APITD1 </italic>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
We could not detect a consistent reduction in cell growth with the other gene constructs tested. Also we could not detect any clear increase in apoptotic cell numbers (Table 1), and no obvious signs of differentiation, although our data do not fully exclude a role for one or more of these genes in the development of neuroblastoma. Noteworthy is also another gene, APITD1, recently localised to this region of interest. APITD1 could be shown to slow down cell growth and induce apoptosis in neuroblastoma cells [11]. We can hypothesise that if a number of genes in this specific region have tumour suppressor activity, a small reduction in expression of all these genes can give a substantial effect on cell growth. A recent study has indeed shown that there are numerous genes from the 1p36-region down-regulated in aggressive neuroblastoma tumours [33].
###end p 73
###begin p 74
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 274 280 274 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 376 381 376 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 424 429 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 471 475 471 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 526 530 526 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
In order to further investigate the ability of ENO1 to slow down cell growth, and to compare the different translation products of ENO1 in a functional manner, we constructed one mutated form of ENO1, ENO1-mut, which would eliminate the possibility for the alternative form MBP-1 to be translated (Fig. 1). We used the ENO1 cDNA vector as a template for in vitro mRNA to make ENO1 mRNA and a shorter form only including the MBP-1-part of the gene to make MBP-1-mRNA. The ENO1-mut construct was used as a template for in vitro ENO1-mut-mRNA.
###end p 74
###begin p 75
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 153 157 153 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 340 344 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 438 439 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 470 475 470 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
We could show that ENO1 mRNA has a strong, dose dependent, inhibitory effect on cell growth in neuroblastoma cells (SK-N-AS). By adding equal amounts of ENO1-mRNA and control-mRNA (EGFP) to the cells, the number of viable cells in the cell culture was decreased by 80% two days after transfection in the ENO1-mRNA-experiment. If 4/5 of the ENO1-mRNA was exchanged with control-mRNA the decrease was 60% two days after transfection (Table 3, Fig. 4). This indicates that ENO1 acts in a dose dependent manner, suggesting that cellular levels of ENO1 might play a crucial role in regulating apoptosis and proliferation in neuroblastoma cells.
###end p 75
###begin p 76
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 476 481 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 566 571 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
Surprisingly the mutated ENO1-mut-mRNA showed very similar effects as the wild type ENO1-mRNA. This might be explained by the fact that ENO1 in fact can bind to the same sites as MBP-1 and act as a transcription factor, even though not as efficiently [22]. Maybe by adding very large amounts of mRNA, this difference is overruled. However, an alternative explanation is that the enolase itself has tumour suppressor activity. This is supported by the observation that 0.3 mug ENO1 mRNA induces a stronger inhibition in cell growth rate (60%) than the same amount of MBP-1-mRNA (40%) in neuroblastoma cells.
###end p 76
###begin p 77
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
A strong effect could also be seen in 293-cells by adding ENO1-mRNA. 80-90% reduction was observed in the 1.5 mug mRNA experiment, while a lower reduction (60%) was observed when 0.3 mug mRNA was used, as was the case with SK-N-AS cells.
###end p 77
###begin p 78
###xml 92 98 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 102 106 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 139 143 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 157 161 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 170 176 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 294 299 292 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 386 391 384 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
A difference between the different mRNAs could also be seen in the 1.5 mug experiment where MBP-1 and ENO1-mut showed a weaker effect than ENO1. Also in the ENO1-mut and MBP-1 experiments, a smaller effect was observed with a lower amount of mRNA (0.3 mug). We conclude that over-expression of ENO1 has the same effect in both neuroblastoma cells and transformed kidney cells, and that ENO1 can function as a general tumour suppressor.
###end p 78
###begin p 79
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 277 281 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 58 63 <span type="species:ncbi:9606">human</span>
However, the transfection of ENO1-mRNA into K562 cells, a human erythroleukemia cell line, shows only minor differences with control mRNA (Table 3, Fig. 4). This indicates that ENO1-mRNA has no general toxicity to cells but seems to work through one or more specific pathways. ENO1-mRNA does not seem to activate any cell death or growth suppression pathway in the lymphoblast cell line K562, as it seems to do in the neuroblastoma cell line SK-N-AS and the transformed kidney cell line 293. But these are indeed very different types of cells, and are likely to be defective in different cellular pathways.
###end p 79
###begin p 80
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 256 260 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 509 513 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 738 742 738 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 815 816 815 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 901 905 901 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 1027 1029 1027 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1089 1094 1089 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 1132 1133 1132 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1259 1260 1259 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1293 1297 1293 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 1349 1354 1349 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
In order to see whether ENO1 was equally expressed in both low stage and advanced neuroblastomas, and also to compare this with the mRNA-levels in neuroblastoma cell lines, we conducted a real-time-PCR-study using Taqman. Surprisingly no difference in the ENO1-mRNA levels could be detected between 1p-deleted tumours and 1p-intact tumours, neither in the cell lines nor in primary Stage 4 neuroblastoma tumours (Fig. 5). The loss of one allele seems either to be compensated in these cells, or the levels of ENO1-mRNA in the aggressive Stage 4 tumours are suppressed by a different mechanism in the 1p-intact Stage 4 tumours. Even though small sample number (11 primary tumours), we could detect a difference (p = 0.01) in the levels of ENO1-mRNA in Stage 4 neuroblastomas compared to Stage 2 neuroblastomas (Fig. 5). This still needs further studies to be confirmed but one could speculate that the ENO1-mRNA level might be of importance in the aggressiveness of neuroblastoma tumours, as seen in non-small cell lung cancer [30]. The cell lines showed a higher relative concentration of ENO1 than any of the primary tumours (Fig. 5). This might be explained by the different surroundings and state of cells in culture compared to primary tumour cells (Fig. 5). The fact that by adding extra ENO1-mRNA to the cell lines, even though they expressed ENO1 already, made them apoptotic, adds to the hypothesis that the levels of this mRNA might be crucial.
###end p 80
###begin p 81
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 400 405 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
We also did a mutation screening of the exonic sequences of ENO1, including exon/intron boundaries, and of the intronic sequences between exons 4-8, in order to cover the region around the alternative translation start of MBP-1, in genomic DNA of 44 primary neuroblastoma tumours of all different stages. However, no mutations could be found in these regions, indicating that changes in the level of ENO1 expression may result from other types of mutations or from changes in regulatory mechanisms.
###end p 81
###begin title 82
Conclusion
###end title 82
###begin p 83
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 559 564 559 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 639 644 639 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 667 675 667 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 737 741 737 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 794 798 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 931 935 931 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
In conclusion, our studies demonstrate that ENO1, a gene mapping to a region commonly deleted in advanced neuroblastoma tumours, can act as a strong tumour suppressor by slowing down the cell growth and inducing apoptosis. Although we could not identify any mutations in the coding sequence and immediate promoter region of the gene in 48 primary tumour samples, our studies suggest that variations in the level of expression of the gene can play a role in regulating apoptosis and cell proliferation in neuroblastoma. To prove the hypothesis of the level of ENO1 expression being crucial, future investigations could involve silencing of ENO1 in neuroblastoma cells in vitro, by gene knock down experiments and/or siRNA targeted to the ENO1-mRNA, to detect whether this, opposite adding extra ENO1-mRNA, increases the growth rate. Deletion of the 1p chromosomal region is obviously one way to achieve a reduction in expression of ENO1, but it is not clear whether a reduction in the expression of the second allele is also necessary through other mechanisms in neuroblastoma.
###end p 83
###begin title 84
Competing interests
###end title 84
###begin p 85
The author(s) declare that they have no competing interests.
###end p 85
###begin title 86
Authors' contributions
###end title 86
###begin p 87
KE carried out the functional studies, the expression studies, the exon sequencing, study design and drafted the manuscript. CK and HC carried out the promoter- and intron sequencing. FZ participated in the in vitro mRNA-design and carried out FACS-analysis. LL participated in tissue culture and FACS analysis. TM participated in the design of the mutation analysis study. PI participated in the design and coordination of the functional study and helped to draft the manuscript.
###end p 87
###begin p 88
All authors read and approved the final manuscript.
###end p 88
###begin title 89
Pre-publication history
###end title 89
###begin p 90
The pre-publication history for this paper can be accessed here:
###end p 90
###begin p 91

###end p 91
###begin title 92
Acknowledgements
###end title 92
###begin p 93
We would like to especially acknowledge Dr. Panos Ioannou that spent a lot of energy on this work, but sadly passed away before the completion of the study.
###end p 93
###begin p 94
###xml 181 189 <span type="species:ncbi:9606">Children</span>
We would like to acknowledge Swegene Genomics Gothenburg for giving us access to their equipment. We gratefully acknowledge the financial support of the Swedish Cancer Society, the Children's Cancer foundation, the King Gustav V Jubilee Clinic Cancer Research Foundation, the Assar Gabrielsson Foundation and Svenska Lakaresallskapet. The work was also partially supported by a grant from the Brockhoff Foundation to PI.
###end p 94
###begin article-title 95
Molecular biology of neuroblastoma
###end article-title 95
###begin article-title 96
Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms
###end article-title 96
###begin article-title 97
Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours
###end article-title 97
###begin article-title 98
Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma
###end article-title 98
###begin article-title 99
###xml 110 115 <span type="species:ncbi:9606">human</span>
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers
###end article-title 99
###begin article-title 100
Variable expression and absence of mutations in p73 in primary neuroblastoma tumors argues against a role in neuroblastoma development
###end article-title 100
###begin article-title 101
###xml 20 25 <span type="species:ncbi:9606">human</span>
Fine mapping of the human preprocortistatin gene (CORT) to neuroblastoma consensus deletion region 1p36.3-->p36.2, but absence of mutations in primary tumors
###end article-title 101
###begin article-title 102
###xml 90 95 <span type="species:ncbi:9606">human</span>
Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours
###end article-title 102
###begin article-title 103
Mutations in the N-terminal domain of DFF45 in a primary germ cell tumor and in neuroblastoma tumors
###end article-title 103
###begin article-title 104
Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2
###end article-title 104
###begin article-title 105
A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours
###end article-title 105
###begin article-title 106
###xml 49 54 <span type="species:ncbi:9606">human</span>
Genomic structure and mutational analysis of the human KIF1B gene which is homozygously deleted in neuroblastoma at chromosome 1p36.2
###end article-title 106
###begin article-title 107
###xml 49 54 <span type="species:ncbi:9606">human</span>
Genomic structure and mutational analysis of the human KIF1Balpha gene located at 1p36.2 in neuroblastoma
###end article-title 107
###begin article-title 108
Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma
###end article-title 108
###begin article-title 109
Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma
###end article-title 109
###begin article-title 110
Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours
###end article-title 110
###begin article-title 111
Cloning, chromosomal localization, physical mapping, and genomic characterization of HKR3
###end article-title 111
###begin article-title 112
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification of human DAN gene, mapping to the putative neuroblastoma tumor suppressor locus
###end article-title 112
###begin article-title 113
###xml 55 60 <span type="species:ncbi:9606">human</span>
Structural organisation and chromosomal mapping of the human Id-3 gene
###end article-title 113
###begin article-title 114
###xml 46 51 <span type="species:ncbi:9606">human</span>
Physical mapping and genomic structure of the human TNFR2 gene
###end article-title 114
###begin article-title 115
###xml 106 111 <span type="species:ncbi:9606">human</span>
###xml 129 134 <span type="species:ncbi:9606">human</span>
Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells
###end article-title 115
###begin article-title 116
Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene
###end article-title 116
###begin article-title 117
###xml 34 39 <span type="species:ncbi:9606">human</span>
Cloning and characterization of a human c-myc promoter-binding protein
###end article-title 117
###begin article-title 118
###xml 125 130 <span type="species:ncbi:9606">human</span>
Identification of alpha-enolase as a nuclear DNA-binding protein in the zona fasciculata but not the zona reticularis of the human adrenal cortex
###end article-title 118
###begin article-title 119
ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1)
###end article-title 119
###begin article-title 120
The c-myc promoter binding protein (MBP-1) and TBP bind simultaneously in the minor groove of the c-myc P2 promoter
###end article-title 120
###begin article-title 121
myc function and regulation
###end article-title 121
###begin article-title 122
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 124 133 <span type="species:ncbi:10090">nude mice</span>
Human breast carcinoma cells transfected with the gene encoding a c-myc promoter-binding protein (MBP-1) inhibits tumors in nude mice
###end article-title 122
###begin article-title 123
###xml 101 110 <span type="species:ncbi:10090">nude mice</span>
Carboxyl-terminal repressor domain of MBP-1 is sufficient for regression of prostate tumor growth in nude mice
###end article-title 123
###begin article-title 124
Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior
###end article-title 124
###begin article-title 125
###xml 76 84 <span type="species:ncbi:9606">patients</span>
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma
###end article-title 125
###begin article-title 126
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
###end article-title 126
###begin article-title 127
A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation
###end article-title 127
###begin title 128
Figures and Tables
###end title 128
###begin p 129
###xml 0 3 0 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A. </bold>
###xml 3 13 3 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1, ENO1</italic>
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1</italic>
###xml 102 106 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 171 175 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl </italic>
###xml 181 185 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cla </italic>
###xml 226 229 224 227 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B. </bold>
###xml 291 294 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Not</italic>
###xml 296 300 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EcoR</italic>
###xml 310 313 308 311 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C. </bold>
###xml 342 346 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 358 361 356 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cla</italic>
###xml 367 370 365 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl</italic>
A. ENO1, ENO1-mut and MBP-1-constructs with translation starts (ATG) and mutated (ATG-->ATC) sites in ENO1-mut at positions 374 and 383 indicated. The mutations introduce Bcl I and Cla I restriction enzyme sites respectively. B. Size determination of cDNA-constructs in pIRES-EGFP-vector by NotI/EcoRI-digest. C. Confirmation of mutations in ENO1-mut DNA by ClaI and BclI digests.
###end p 129
###begin p 130
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 291 296 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
FACS results of SK-N-AS cells two days after transfection of empty pIRES-EGFP-vector (black line) and ENO1-pIRES-EGFP (grey line). The cells were TUNEL stained using TMR-red labelled nucleotides to label all apoptotic cells red. There is a clear increase of the number of red cells (FL2) in ENO1 transfected cells compared to empty vector control.
###end p 130
###begin p 131
###xml 232 235 232 235 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A: </bold>
###xml 653 656 653 656 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B: </bold>
###xml 794 796 794 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8</sup>
###xml 815 817 815 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
Cell growth curves of cDNA-transfected cells monitored for 3 days after transfection. The average number of cells in 8 separate experiments is shown at each time point for each construct. Standard deviation is indicated with a bar. A: Cell growth after transfection of five different constructs compared to empty vector (pIRES-EGFP) control in SK-N-AS cells. Using Students T-test, no significant differences in cell number compared to control cells could be detected for the first two days after transfection for any of the constructs, three days after transfection DFFA (p = 0.002), CORT (p = 0.004) and PGD (p < 0.001) showed significant difference. B: Cell growth after transfection of ENO1 compared to empty vector control. Significant differences in cell number was detected day 1 (p < 10-8) and day 2 (p < 10-4), the difference was not significant day 3 after transfection.
###end p 131
###begin p 132
###xml 77 86 77 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 295 298 295 298 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A: </bold>
###xml 347 351 347 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 371 375 370 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 398 402 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 418 422 415 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 450 454 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 581 585 577 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 611 615 607 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 761 764 757 760 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B: </bold>
###xml 833 837 828 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 839 848 834 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1-mut </italic>
###xml 852 858 847 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 930 935 925 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 939 945 934 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 985 990 980 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 994 1003 989 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1-mut </italic>
###xml 1033 1036 1028 1031 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C: </bold>
###xml 1102 1106 1096 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 1108 1117 1102 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1-mut </italic>
###xml 1121 1127 1115 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 1199 1204 1193 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 1208 1214 1202 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP-1 </italic>
###xml 1285 1290 1279 1284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 1294 1303 1288 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1-mut </italic>
Cell growth curves of cell lines SK-N-AS, 293 and K562 after transfection of in vitro transcribed mRNA and monitoring for 4 days after transfection. The average number of cells in 8 separate experiments is shown at each time point for each construct. Standard deviation is indicated with a bar. A: Two different amounts of mRNA have been used for ENO1-mRNA: 1.5 (1.5 mug ENO1-mRNA) or 0.3 (0.3 mug ENO1-mRNA + 1.2 mug EGFP-mRNA), compared to 1.5 mug EGFP-mRNA and lipofectamine only. There is strong statistical significance (p << 0.001) for difference in cell numbers between the ENO1-mRNA-experiments and the EGFP-mRNA experiments in SK-N-AS and 293-cells (exact p-values for each day are listed in Table 3), in K562 cells the difference was not significant. B: Cell growth curves of SK-N-AS cells after transfection of 1.5 mug of ENO1, ENO1-mut and MBP-1 mRNAs and monitoring for 4 days. The difference in cell numbers between ENO1 and MBP-1 was significant for day 2-4 (p = 0.02), ENO1 and ENO1-mut did not significantly differ. C: Cell growth curves of SK-N-AS cells after transfection of 0.3 mug ENO1, ENO1-mut and MBP-1 mRNAs and monitoring for 4 days. The difference in cell numbers between ENO1 and MBP-1 was significant for day 2 (p = 0.006), 3 (p = 0.001) and 4 (p = 0.02). ENO1 and ENO1-mut did not significantly differ.
###end p 132
###begin p 133
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1 </italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB </italic>
Expression of ENO1 in neuroblastoma cell lines and primary neuroblastoma tumours using real-time-PCR. Relative concentrations of ENO1-mRNA in relation to the concentration of the housekeeping gene GUSB for each sample are indicated on the y-axis. The samples are grouped into five groups: neuroblastoma cell lines, with and without 1p-deletion; stage 2 tumours; stage 4 tumours, with and without 1p-deletion. The 1p-deletion-status of each sample is indicated at the bottom. For each group the average value is indicated by a dotted line. A difference in expression could be detected between stage 2 tumours and stage 4 tumours (p = 0.01). No difference in expression could be detected between 1p-deleted samples and not 1p-deleted samples.
###end p 133
###begin p 134
Induction of apoptosis two days after transfection of cDNA constructs in SK-N-AS neuroblastoma cells.
###end p 134
###begin p 135
Effects of various cDNA constructs on cell growth after transfection into neuroblastoma and other tumour cell lines.
###end p 135
###begin p 136
###xml 11 20 11 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Effects of in vitro transcribed ENO1 mRNA constructs on cell growth after transfection into neuroblastoma (SK-N-AS), 293 and K562 cell lines.
###end p 136

